Early access to bedaquiline for extensively drug-resistant (XDR) and pre-XDR tuberculosis. Issue 1 (25th July 2019)

• Record Type: Journal Article
• Authors: Vasilyeva, Irina; Mariandyshev, Andrei; Kazennyy, Boris; Davidavičienė, Edita; Lounis, Nacer; Keim, Sofia
• Is Part Of: European respiratory journal. Volume 54:Issue 1(2019)
• Publication Date: 2019-07-25
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.02208-2018
• Languages: English
• ISSNs: 0903-1936

Abstract

Globally in 2016, 19% of previously treated tuberculosis (TB) cases and 4.1% of newly diagnosed cases were reported to be resistant to isoniazid and rifampicin (multidrug-resistant (MDR)-TB) or rifampicin alone (rifampicin-resistant TB) [1]. In 2017, 8.5% of MDR-TB cases were caused by extensively drug-resistant (XDR)-TB [1], defined as MDR-TB with additional resistance to a fluoroquinolone (FQ) and a second-line injectable drug (SLI) (amikacin, kanamycin or capreomycin). TB drug resistance, especially XDR-TB, is associated with poorer treatment outcomes [1–3]. This letter presents final safety and efficacy data from an early-access study of bedaquiline for treating (pre-)XDR-TB http://bit.ly/2Ff4qyl